Dr. Barry Dworkin

Phase 2 study with a long way to go suggests that a desert-toad-derived psychedelic drug in nasal spray format may provide relief for people with treatment-resistant depression.

Medical Mythbusting Commentary for November 2, 2026

Source:
A fast-acting nasal spray offers hope for hard-to-treat depression: study

Reference:
Single Intranasal Administration of the Psychedelic Mebufotenin for Treatment-Resistant Depression

Related posts:

  1. New rapid five-day protocol application of transcranial magnetic stimulation brain for the treatment of treatment-resistant depression seems to be of equal efficacy of the standard six- week treatment cycle.
  2. New understanding how cannabis may affect brain chemistry and its relation to mood disorder risk
  3. Ketamine contributes to understanding of pathways that can alleviate depression
  4. Phase 1 anti-cancer vaccine study shows great promise